vs
安捷伦科技（A）与COMMUNITY HEALTH SYSTEMS INC（CYH）财务数据对比。点击上方公司名可切换其他公司
COMMUNITY HEALTH SYSTEMS INC的季度营收约是安捷伦科技的1.7倍（$3.1B vs $1.8B）。安捷伦科技净利率更高（17.0% vs 3.5%，领先13.4%）。安捷伦科技同比增速更快（7.0% vs -4.8%）。安捷伦科技自由现金流更多（$175.0M vs $172.0M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs -0.5%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
社区卫生系统公司总部位于美国田纳西州富兰克林，是财富500强企业。按急症护理机构数量计算，该公司曾是美国最大的综合医院医疗服务提供商。2014年它旗下有约200家医院，到2021年机构数量缩减至约85家。
A vs CYH — 直观对比
营收规模更大
CYH
是对方的1.7倍
$1.8B
营收增速更快
A
高出11.8%
-4.8%
净利率更高
A
高出13.4%
3.5%
自由现金流更多
A
多$3.0M
$172.0M
两年增速更快
A
近两年复合增速
-0.5%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $3.1B |
| 净利润 | $305.0M | $110.0M |
| 毛利率 | 52.6% | 85.6% |
| 营业利润率 | 19.6% | 14.5% |
| 净利率 | 17.0% | 3.5% |
| 营收同比 | 7.0% | -4.8% |
| 净利润同比 | -4.1% | 254.9% |
| 每股收益（稀释后） | $1.07 | $0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACYH
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $3.1B | ||
| Q3 25 | $1.7B | $3.1B | ||
| Q2 25 | $1.7B | $3.1B | ||
| Q1 25 | $1.7B | $3.2B | ||
| Q4 24 | $1.7B | $3.3B | ||
| Q3 24 | $1.6B | $3.1B | ||
| Q2 24 | $1.6B | $3.1B |
净利润ACYH
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $110.0M | ||
| Q3 25 | $336.0M | $130.0M | ||
| Q2 25 | $215.0M | $282.0M | ||
| Q1 25 | $318.0M | $-13.0M | ||
| Q4 24 | $351.0M | $-71.0M | ||
| Q3 24 | $282.0M | $-391.0M | ||
| Q2 24 | $308.0M | $-13.0M |
毛利率ACYH
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 85.6% | ||
| Q3 25 | 51.1% | 85.1% | ||
| Q2 25 | 51.9% | 85.0% | ||
| Q1 25 | 53.5% | 84.5% | ||
| Q4 24 | 53.9% | 84.5% | ||
| Q3 24 | 54.2% | 84.8% | ||
| Q2 24 | 54.4% | 84.6% |
营业利润率ACYH
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 14.5% | ||
| Q3 25 | 20.7% | 7.9% | ||
| Q2 25 | 18.0% | 16.3% | ||
| Q1 25 | 22.4% | 9.0% | ||
| Q4 24 | 24.0% | 8.5% | ||
| Q3 24 | 21.1% | -6.6% | ||
| Q2 24 | 23.1% | 7.6% |
净利率ACYH
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 3.5% | ||
| Q3 25 | 19.3% | 4.2% | ||
| Q2 25 | 12.9% | 9.0% | ||
| Q1 25 | 18.9% | -0.4% | ||
| Q4 24 | 20.6% | -2.2% | ||
| Q3 24 | 17.9% | -12.7% | ||
| Q2 24 | 19.6% | -0.4% |
每股收益（稀释后）ACYH
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.82 | ||
| Q3 25 | $1.18 | $0.96 | ||
| Q2 25 | $0.75 | $2.09 | ||
| Q1 25 | $1.11 | $-0.10 | ||
| Q4 24 | $1.23 | $-0.53 | ||
| Q3 24 | $0.97 | $-2.95 | ||
| Q2 24 | $1.05 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $260.0M |
| 总债务越低越好 | $3.0B | $10.4B |
| 股东权益账面价值 | $6.9B | $-1.4B |
| 总资产 | $12.8B | $13.2B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资ACYH
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $260.0M | ||
| Q3 25 | $1.5B | $123.0M | ||
| Q2 25 | $1.5B | $456.0M | ||
| Q1 25 | $1.5B | $431.0M | ||
| Q4 24 | $1.3B | $37.0M | ||
| Q3 24 | $1.8B | $33.0M | ||
| Q2 24 | $1.7B | $39.0M |
总债务ACYH
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $10.4B | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | $11.5B | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益ACYH
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $-1.4B | ||
| Q3 25 | $6.4B | $-1.5B | ||
| Q2 25 | $6.1B | $-1.6B | ||
| Q1 25 | $6.0B | $-1.9B | ||
| Q4 24 | $5.9B | $-1.9B | ||
| Q3 24 | $5.9B | $-1.8B | ||
| Q2 24 | $6.2B | $-1.4B |
总资产ACYH
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $13.2B | ||
| Q3 25 | $12.2B | $13.2B | ||
| Q2 25 | $12.2B | $13.6B | ||
| Q1 25 | $11.9B | $13.9B | ||
| Q4 24 | $11.8B | $14.1B | ||
| Q3 24 | $11.0B | $13.9B | ||
| Q2 24 | $10.9B | $14.4B |
负债/权益比ACYH
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $266.0M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $172.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 5.5% |
| 资本支出强度资本支出/营收 | 5.2% | 3.0% |
| 现金转化率经营现金流/净利润 | 0.88× | 2.42× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $208.0M |
8季度趋势，按日历期对齐
经营现金流ACYH
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $266.0M | ||
| Q3 25 | $362.0M | $69.0M | ||
| Q2 25 | $221.0M | $88.0M | ||
| Q1 25 | $431.0M | $120.0M | ||
| Q4 24 | $481.0M | $216.0M | ||
| Q3 24 | $452.0M | $67.0M | ||
| Q2 24 | $333.0M | $101.0M |
自由现金流ACYH
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $172.0M | ||
| Q3 25 | $259.0M | $4.0M | ||
| Q2 25 | $107.0M | $-3.0M | ||
| Q1 25 | $334.0M | $35.0M | ||
| Q4 24 | $388.0M | $107.0M | ||
| Q3 24 | $360.0M | $-3.0M | ||
| Q2 24 | $230.0M | $13.0M |
自由现金流率ACYH
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 5.5% | ||
| Q3 25 | 14.9% | 0.1% | ||
| Q2 25 | 6.4% | -0.1% | ||
| Q1 25 | 19.9% | 1.1% | ||
| Q4 24 | 22.8% | 3.3% | ||
| Q3 24 | 22.8% | -0.1% | ||
| Q2 24 | 14.6% | 0.4% |
资本支出强度ACYH
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 3.0% | ||
| Q3 25 | 5.9% | 2.1% | ||
| Q2 25 | 6.8% | 2.9% | ||
| Q1 25 | 5.8% | 2.7% | ||
| Q4 24 | 5.5% | 3.3% | ||
| Q3 24 | 5.8% | 2.3% | ||
| Q2 24 | 6.5% | 2.8% |
现金转化率ACYH
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 2.42× | ||
| Q3 25 | 1.08× | 0.53× | ||
| Q2 25 | 1.03× | 0.31× | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
CYH
| Managed Care And Other Third Party Payors | $1.5B | 49% |
| Medicare Managed Care | $570.0M | 18% |
| Medicare | $512.0M | 16% |
| Medicaid | $464.0M | 15% |
| Self Pay Revenue | $34.0M | 1% |
